Friday, October 10, 2025

Novartis Appoints Manfred Heinzer as New Chairman of the Management Board in Germany

Novartis Germany today announced that Manfred Heinzer will assume the role of Chairman of the Management Board effective November 1, 2025. He succeeds Heinrich Moisa, who is leaving the company after 17 successful years.

In his new role, Heinzer will report directly to Dr. Patrick Horber, President International, Novartis. Under Moisa’s leadership, the German organization has been optimally positioned for its next phase of growth.

Dr. Horber expressed his appreciation for Moisa’s contributions:

“We sincerely thank Heinrich for his many years of commitment and dedication to Novartis. At the same time, we are delighted that Manfred will take over leadership of our German organization – a country where we plan to launch a double-digit number of new drug molecules over the next five years.”

With more than 30 years of international experience at major pharmaceutical companies including GlaxoSmithKline, Roche, Gilead, and Amgen, Heinzer brings extensive expertise in oncology, inflammatory, and rare diseases. Most recently, he served as Vice President and General Manager of Amgen Germany, successfully expanding the company’s business during his five-year tenure.

“I am excited to join Novartis Germany,” said Heinzer. “Novartis stands for innovation, patient focus, and social responsibility. I look forward to working with the team to make urgently needed medicines accessible to all patients.”

The new Novartis Germany Management Board will consist of Manfred Heinzer (Chairman), Romain Lege, and Nicole Struck.

With this appointment, Novartis underscores its ambition to further strengthen healthcare in Germany and expand access to innovative therapies.